IC5 Management of GI Flashcards

(80 cards)

1
Q

what are the emesis pathways in CINV

A

peripheral pathway
- chemotherapy induces enterochromaffin cells in the GI to release serotonin –> bind to 5HT3 receptors of the vagal afferent triggering ACUTE CINV

central pathway
- chemotherapy induces chemoreceptor trigger zone (CTZ) in the CNS –> substance P release –> activate NK1 receptor –> trigger DELAYED CINV.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are the different types of CINV?

A

acute
delayed
breakthrough
anticipatory
refractory

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

describe acute CINV

A

onset 1-2 hours after chemotherapy
peak 5-6 hours
resolution 24hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

describe delayed CINV

A

onset 48-72 hours
diminish after 1-3 days.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

describe anticipatory CINV

A

uncontrolled emesis prior to chemotherapy, associated with environmental cues eg smell of chemotherapy room

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

describe breakthrough CINV vs refractory CINV

A

breakthrough = N/V despite preventive therapy

refractory = N/V in subsequent cycles when antiemetic prophylaxis or rescue therapy has failed in previous cycles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what are the patient risk factors for CINV?

A

1) young age <50
2) female gender
3) hx of chemo related emesis
4) hx of motion sickness
5) hx of emesis in past pregnancy
6) anxiety
7) low prior alcohol intake <1 glass per day

(1 and 2 impt, commonly missed out)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what is the low risk antiemetic regimen

A

5HT3
or
DEXA
or DOPA
(no need for delayed treatment)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what is the high risk antiemetic regiment

A

d1 (acute) GIVEN BEFORE CHEMOTHERAPY
NK1 + 5HT3 + DEXA
+/- olanzapine

(delayed)
DEXA (d2-4)
+/- olanzapine (d2-4 if added previously)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what is the minimal risk antiemetic regimen

A

should not be offered routine prophylaxis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what is the moderate risk antiemetic regiment

A

d1 (acute)
5HT3 + DEXA

(delayed)
DEXA (d2-3)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what is the dose of nk1 antagonist

A

aprepitant (emend)
PO 125mg day1
80mg d2,3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is the dose of 5HT3 antagonist

A

IV/PO ondansetron 8-16mg OD d1
IV/PO granisetron 1mg OD d1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is the dexamethasone dose

A

IV/PO 12mg OD day 1
IV/PO 8mg OD day 2 onwards

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what is the combination 5HT3 + NK1 antagonist dose?

A

akynzeo = netupitant 300mg + palonosetron 0.5mg

PO 1 cap OD day 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is the dopamine antagonist dose

A

metoclopramide IV/PO 10mg OD-TDS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

side effects of nk1 receptors antagonist (common)

A

fatigue
weakness
hiccups
nausea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is the moa of nk1 receptor antagonist

A

prevents substance p from binding to the receptor thus reducing vagal afferent signals to exert antiemetic effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

side effects of akynzeo

A

headache
constipation
mild fatigue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

drug interactions of nk1 receptors antagonist

A

warfarin (2c9 induction)
steroids (3a4 inhibition) eg budesonide
benzodiazepines (increased BZP conc due to reduced metabolism; 3a4 inhibition) eg diazepam

some chemotherapy agents like ifosfamide (decrease ifosfamide metabolism)

due to inhibition of CYP3A4 and induction of 2C9

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

moa of 5ht3 receptor antagonists?

A

blocks 5ht3 receptors peripherally in the gi tract
and
centrally in the medulla

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

what are the comparisons between the diff 5ht3RA available?

A

ondansetron = shortest acting
granisetron = intermediate acting (expensive)
palanosetron = longest acting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

SE of 5HT3 RA

A

headache and consitpaiton

rare: QTC prolongation
(caution in patients with underlying cardiac disease eg bradycardia, CHF, electrolyte abnormalities.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

ADR of dexa

A

common: transient increase in glucose, insomnia (dont take late at night),
anxiety,
gastric upset (take with food)

less common: psychosis,
reactivation of ulcers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
olanzapine moa
antagonist of dopamine, serotonin, histamine, cholinergic
22
dose of olanzapine
5 to 10mg OD consider 2.5mg for elderly
23
ADR of olanzapine
fatigue, sedation, postural hypotension, anticholinergic SE
24
indications for metoclopramide
used for acute CINV therapy in low emetic regimens used for breakthrough CINV
25
moa of metoclopramide
Blockade of dopamine receptors in the chemoreceptor trigger zone; stimulation of cholinergic activity in the gut, increasing (forward) gut motility; and antagonism of peripheral serotonin receptors in the intestines.
26
ADR of metoclopramide
mild sedation diarrhoea EPSE (dystonia = muscle stiffness and spasms, twitching or difficulty in speaking or swallowing; akathisia =restlessness )
27
counselling points with metoclopramide
avoid taking with olanzapine increases risk of EPSE and toxicity - tardive dyskinesia = Uncontrollable movements (such as in the face, tongue, jaw or other parts of the body) - neuromalignant syndrome = fever, stiffness, confusion, irregular BP IMPORTANT to separate during the first two days of their antiemetic regiment + not a big concern since PRN dosing and low dose. counsel patient to watch for these symptoms.
27
indication for benzodiazepines
anticipatory CINV
28
moa of BZP for CINV
BIND to BZP receptors on post synaptic GABA neuron to enhance inhibitory effect of GABA
29
dosing for BZP for CINV
PO alprazolam 0.5-1mg OR PO lorazepam 0.5-2mg on the night before chemotherapy AND 1-2h before chemo
30
ADR of BZP
drowsy dizziness hypotension anterograde amnesia paradoxical reactions caution elderly = risk of falls
31
what are some adjunctive agents for CINV
for refractory CINV = butyrophenones (haloperidol) = phenothiazines (prochloperazine, promethazine, chlorpromazine) both block dopamine receptors in CTZ
32
dose AND side effect of butyrophenones (haloperidol)
po / iv 0.5 mg q4-q6h sedation, EPSE, etc
33
dose and side effect of phenothiazines
prochloperazine po 10mg TDS- QDS prn adr: SEDATION, hypotension, EPSE (including dystonia, akathisia) - same as meto
34
when to consider IV
IF ongoing vomiting
35
considerations for breakthrough CINV
fluid repletion and hydration for losses. reassess next cycle antiemetics cnsider use of several agents utilizing different mechanism of actions (AND diff drug class) if necessary check for adherence
36
non phx strategies for CINV
1) take small, frequent meals 2) avoid greasy, spicy, very sweet/salty food OR food with strong flavours/smells 3) sip small amounts of fluid instead of full glass 4) avoid caffeinated beverages 5) avoid lying flat 2h after eating
37
management of multi day regimens
Give appropriate prophylactic therapy for expected emetogenicity on each day of chemotherapy administration * Continue delayed prophylaxis alone for 2-3 days after completion of chemotherapy if indicated
37
management of anticipatory CINV
use optimal anti emetic therapy during every cycle of treatment relaxation and systematic desensitisation hypnosis/guided imagery music therapy acupuncture/acupressure use of BZP before treatment
38
complications of chemotherapy induced diarrhoea
abnormal electrolytes inappropriate fluid balance malnutrition renal failure weight loss fatigue dehydration
39
risk factors for CID
>65 yo female ECOG performance status ≥2 bowel inflammation/malabsorption bowel malignancy biliary obstruction x6
39
predictive factors for CID
1st chemo chemo duration more than 3 weeks concomitant neutropenia associated sx: anemia, anorexia, vomiting, mucositis
40
mechanism of CID
direct damage and inflammation of the intestinal mucosa resulting in imbalance between absorption and secretion.
41
severity grading for CID
GRADE 1) increase <4 per day above baseline 2) 4-6 + limit ADL 3) ≥7 + hospitalisation + limit self care 4) life threatening and urgent intervention needed
42
criteria for complicated vs uncomplicated CID?
uncomplicated - grade 1 and 2 - no complications complicated - grade 3 and 4 - grade 1 and 2 with complicating sx of atleast ≥1 = cramps, grade 2 N/V = fever, sepsis, neutropenia = frank bleeding (eg haemorrhoids, fissures) = dehydration
43
mechanism of loperamide
opioid inhibiting smooth muscle contraction in intestine to decrease motility
43
management of uncomplicated diarrhoea
for grade 2 = withhold chemo until sx resolve OR reduce dose diet = oral rehydration with 8-10 glass of clear liquid loperamide 4mg STAT then 2mg every 4h or after each episode (no max dose), continue until 12hour free of diarrhoea... if improvement after 12-24h, continue diet modification and begin to add solid foods if persist after 12-24h, - loperamide 2mg q2h - PO abx (IMPT) - if progress to complicated = treat accordingly - if after another 12-24 (with loperamide), stop loperamide, start octreotide or second line agent (FYI).
43
goals of therapy for CID
decrease mortality and morbidity improve QOL and ADL improve recovery of intestinal mucosa decrease hospitalisation
44
management of complicated diarrhoea
withhold chemotherapy and restart with lower dose octreotide SC 100-150mcg TDS or 25-50mcg/hr continuous IV = increments of 50mcg after 24h = increase to max 500mg TDS start IV fluid hydration start IV abx (cipro x7days)
44
adr of loperamide
n/v dry mouth dizzinss drowsiness rash constipation bloating abdominal pain
45
define irinotecan ACUTE diarrhoea
EARLY ONSET onset within 24h after admin mean sx duration 30min dose dependent = more sx during infusion mainly due to acute cholinergic properties
45
ADR of octreotide (IMPT)
bradycardia, arrhymia constipation, abdo pain, n/v headache, dizziness enlarged thyroid
46
octreotide moa
decrease hormone secretion = 1)increased transit time within intestines, 2) decreases secretion of fluid, 3) increased absorption of fluids and electrolytes
46
non phx management of CID
PROBIOTICS with lactobacillus (IMPT) avoid alcohol, caffeine, **fruit juice**, lactose foods, spicy foods, high fibre foods, high fat foods, dietary supplements with high osmolarity eat small frequent meals BRAT diet (banana, rice, applesauce, toast) >3L of clear fluids containing sugar and salt avoid lactose foods a week after CID resolution
46
mechanism of irinotecan diarrhoea
conversion in liver to active metabolite SN38 - enterohepatic recycling - 100-1000x more cytotoxic in parent drug + main diarrhoea cause causing crypt ablation, villus blunting, atrophy of epithelium of small/large intestine
46
risk factors for irinotecan diarrhoea
1) homozygous for UGT1A1*28 = decreased expression of UGT1A1, responsible for conversion to SN38-G (deactivation by glucoronidation) 2) bacteria in gut produce beta glucoronidase = reactive SN38-G to SN38 via deconjucation
47
management of irinotecan associated ACUTE diarrhoea including MOA
SC/IV atropine 0.25-1mg (max 1.2; usually sc) MOA; inhibit acetylcholine at msucarinic receptor via competitive antagonism. - note irinotecan is a reversible, selective acetylcholine esterase = cause cholinergic response
47
SE of atropine, C/I
insomnia, dizziness tachycardia, blurred vision, dry mouth, consipation contrdinciation in glaucoma
47
define irinotecan DELAYED diarrhoea
LATE ONSET after 24h from admin not dose or frequency dependent - median 6 days with q3week dosing - median 11 days with weekly dosing
47
management of irinotecan DELAYED diarrhoea
loperamide 4mg with first loose stop then 2mg q2h (4mg q4h (night)) until 12h of no bowel movement
48
factors increasing risk of chemo induced constipation
1) lower fluid intake / dehydration 2) loss of appetite / anorexia 3) lack of fibre/bulk forming foods 4) vitamin or mineral supplements eg iron or calcium pills 5) overuse of laxatives 6) low lv of phy activity / alot of bed rest 7) thyroid problems 8) depression 9) high serum calcium/potassium 10) cancer growing into large intestine/pressing into spinal cord
49
sx of chemo induced constiaption
* Bloating or feeling of fullness * Cramping or pain * Gas, or flatulence * Belching * Loss of appetite * No regular bowel movement for 2 or more days * Straining to have a bowel movement * Small hard stools that are difficult to pass * Rectal pressure * Leakage of small amounts of stool resembling diarrhea * Swollen, or distended, abdomen * Nausea or vomitng
50
drugs that increase consitpaiton risk
opioids chemo drugs (vinca alkaloids: vincristine, vinblastine, vinorelbine) antinausea (5ht3 receptors antagonists) anticonvulsants
50
non phx prevention of consitpaiton
eat more fibre eat natural laxatives increase phy activity
51
phx management of constipation
stimulant laxatives - Senna 15mg ON bulk forming laxatives - fibrogel 1 sachet BD (isphagula husk) osmotic laxatives /stool softener - lactulose 10-15ml TDS - macrogol (forlax 1 sachet BD) enemas and suppositories - enemas clean out bowel or deliver laxatives eg fleet phosphate enema
52
when should suppositories and enemas be avoided
low WBC or platelet count due to infection risk OR bleeding.
53
grading for mucositis induced by chemo
WHO: 0) NO EVIDEENCE 1) erythema and soreness 2) ulcers, can eat solids 3) ulcers, liquid diet 4) ulcers, cannot PO 5) n/a CCTAE 0) NA 1) Asymptomatic or mild, no intervention 2) moderate pain, modified diet 3) severe pain, interfere with PO 4) life threatening 5) death
54
risk factors for chemo induced mucositis
PATIENT RELATED - autoimmune disorder - diabetes - female - folic acid or vit b12 deficiency CHEMOTHERAPY (risk increases with any other factors that increase dose and frequency) RADIOTHERAPY (furhter increased with smoking, alcohol, or presence of xerostomia/infection)
55
goals of therapy for chemo induced mucositis
prevent and decrease severity manage pain and associated sx prevent chemo delays or dosage reductions
56
recommend measures to prevent mucositis
1) paliferm after high dose chemo and TBI for autologous HSCT 2) benzydramine hcl mouthwash after radiation 3) oral cryotherapy
57
palifermin dosing
keratinocyte growth factor - reduce duration and severity - iv 60mcg/kg/day for three consecutive days before and after myelotoxic therapy (total 6) = third dose 24-48h prior = forth dose on same day as HSCT and within 4 days of third dose
58
how does oral cryotherapy help
reduces mucositis by causing vasoconstriction and decreasing blood flow to the GI mucosal
59
recommended treatment strategies for mucositis
Oracare Suspension (Nystatin 125,000U, Tetracycline 62.5mg, hydrocortisone 5mg, diphenhydramine 11.5mg/10mL) Mylocaine suspension (diphenhydramine 11.5mg, lignocaine 16.7mg/10mL) Morphine sulfate solution 1mg/mL
60
counselling for treatment strateiges for mucositis
mylocaine and morphine meant to stop pain before meals. take 15min - 1h before then oracare after food to remove bacteria SAFE TO SWLLOW AVOID ALCOHOL BASED
61
other formulations for mucositis treatment
oracort (lidocaine + triamcinolone) soragel (choline salicylate) difflam spray (benzydamine) difflam gargle
62
non phx tx of mucostitis
oral 7 mouthwash bioxtra mouthwash AVOID ALCOHOL BASED like listerine = drying effect may cause xerostomia (mouth dryness)